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Abstract
Background and Aims
EASL/AASLD hepatic encephalopathy (HE) guidelines proposed the alternative use of the
term ‘Covert HE’ combining minimal HE (mHE) and Grade 1 HE into a single entity. How-
ever, longitudinal data to indicate that these are indeed a single entity are lacking. The aims
of this study were to determine whether the occurrence of complications of cirrhosis requir-
ing hospital admission and mortality were similar in these sub-groups of patients.
Methods
Clinically-stable cirrhotic patients (n = 106) with no previous history of ‘Overt HE’were
included over a 2-year period and classified as having no HE (n = 23), mHE (n = 39) or Grade
1 HE (n = 44). Standard biochemistry, venous ammonia, bacterial DNA and neutrophil func-
tion were measured at inclusion and the patients were followed for a mean of 230±95 days.
Results
Patients with Grade 1 HE had significantly more complications requiring hospitalisation
(infection 9/18/34%; HE 4/8/18%; other 13/10/11%; P = 0.02) and significantly greater mor-
tality (4/5/20%; P = 0.04) compared to patients with no HE or mHE respectively. Patients
with mHE and grade 1 HE had similar ammonia levels, but higher than the no HE group
(P<0.001). MELD score was similar between groups but Grade 1 HE patients had increased
frequency of bacterial translocation (P = 0.06) and neutrophil spontaneous respiratory burst
(P = 0.02) compared to patients with mHE.
Conclusions
The results of this study show for the first time that ‘Covert HE’ is a heterogeneous entity
with significantly greater hospitalisations and mortality in the Grade 1 HE patients compared
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Introduction
The presence of hepatic encephalopathy (HE) in patients with cirrhosis increases mortality
with the worsening of HE grade [1–4]. Previous studies have been limited to either patients
with ‘overt HE’ comparing grade 1–2 HE and grade 3–4 HE or to studies in patients with mini-
mal hepatic encephalopathy (mHE) only. mHE patients are at increased risk of developing
‘overt HE’ compared to cirrhotic patients with no HE [5, 6] and have been shown to have a
poor quality of life [7]. Bajaj et al and the recent EASL/AASLD guidelines on HE proposed the
alternative use of the term ‘Covert HE’ combining mHE and Grade 1 HE into a single entity [8,
9]. The rationale for this proposal was that it is often difficult to diagnose Grade 1 HE because
the diagnostic criteria are difficult to apply in clinical practice. The HE guidelines recom-
mended a data-driven approach to evaluate whether the term ‘Covert HE’ is informative and
clinically valuable as longitudinal data to indicate whether these are indeed a single entity are
lacking.
Intercurrent complications of cirrhosis such as ascites, variceal bleeding, infection and HE
are predictors of poor prognosis in cirrhotic patients. Infection is a common reason for hospital
admission and progression to HE and death in cirrhotic patients. Impaired neutrophil function
is observed in these patients [10] and ammonia has been shown to play a part by inducing
impaired phagocytosis and increased neutrophil spontaneous oxidative burst [11]. The grade
of HE is proposed to be associated with ammonia levels [12], although a consistent correlation
between plasma ammonia levels and the grade of HE is not observed; a synergetic effect of
inflammation and infection is also of importance [13, 14].
The aims of this prospective study were to determine whether the two entities, mHE and
grade 1 HE are clinically and pathophysiologically homogeneous. We hypothesised that
patients with grade 1 HE had more liver related complications requiring hospitalisation com-
pared to patients with mHE. The occurrence of complications and mortality were considered
as the main end-points of the study. For mechanistic linkage, ammonia levels, inflammatory
markers and neutrophil function were also evaluated and compared between the two sub-
groups of cirrhotic patients.
Patients and Methods
This study was performed between 2008 and 2010 at University College London Hospitals.
Ethics approval was obtained from University College London Hospitals Ethics Committee
and all the participants provided written informed consent in accordance with the Helsinki
Declaration. The study was as a part of a protocol set up to define the role of neutrophil dys-
function in cirrhosis and data from 8 of the patients included here have been published previ-
ously [15]. None of the HE data described here have been published previously.
Subjects, study design and ethics
Patients were included if they were>18 and<75 years of age and had a clinical, radiological,
or histological diagnosis of cirrhosis. Exclusion criteria were severe complications of liver dis-
ease including gastrointestinal bleeding, hepatorenal syndrome, hepatic encephalopathy (grade
2 or higher), bacterial infection, spontaneous bacterial peritonitis, treatment with systemic
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antibiotics, probiotics or norfloxacin for selective gut decontamination, hepatic or extrahepatic
malignancy, any immunomodulatory or steroid therapy, any organ failure within the past
30-days. Patients known to be drinking alcohol at the time of study inclusion were also
excluded. Liver function tests, white blood cell count (WBC), venous ammonia, bacterial DNA,
neutrophil respiratory burst and phagocytosis were measured at inclusion and the patients
were followed up to a year for the occurrence of complications requiring hospitalisation and
death.
Diagnosis of Grade 1 HE and mHE
The presence or the absence of Grade 1 HE was established by means of careful neurological
examination using the West-Haven criteria. Each patient was examined by one hepatologist
(RJ). The diagnosis was based on the neurological findings of lack of awareness, euphoria or
anxiety, shortened attention span and/or impaired performance of addition. EEG, psychomet-
ric hepatic encephalopathy score (PHES) and critical flicker frequency (CFF) were used in
screening for mHE. Patients were classified as having mHE if at least one of the three tests was
abnormal. EEG was recorded for 10-minutes, in a relaxed condition with eyes-closed and using
the standard 21 electrodes. EEGs were classified as normal or abnormal based on the spectral
criteria described previously [16]. Psychometric performance was measured using the PHES
test (number connection tests A and B, the digit symbol subtest of the Wechsler adult intelli-
gence scale, line tracing and serial dotting tests) as described previously [17]. The tests were
scored using age and education-adjusted UK scores. The PHES test were described as abnormal
if the score was<-4 [17]. CFF was measured using the ‘Hepatonorm analyzer’ and abnormality
was defined using a cut-off of< 39 [18].
Biochemical analyses
Blood samples for bilirubin, albumin, INR, sodium, creatinine, WBC, and ammonium were
analyzed immediately following collection by routine analytical methods. Blood samples for
the assessment of bacterial DNA, neutrophil respiratory burst and phagocytosis were asepti-
cally collected into pyrogen-free tubes, placed immediately on ice, centrifuged, separated and
stored at -80°C until analysis.
Bacterial DNA
Bacterial DNA was assessed using specific polymerase chain reaction for the conserved region
of the 16S ribosomal RNA prokaryote gene as previously described [19].
Neutrophil isolation
Neutrophils were harvested from healthy volunteers. Patient plasma was incubated with these
cells as previously described [10]. The Phagoburst kit (Orpegen Pharma, Heidelberg, Germany)
was used to determine the percentage of neutrophils that produce reactive oxidants and the
Phagotest (Orpegen Pharma) was used to measure phagocytosis by using FITC-labelled opso-
nized E. coli bacteria as previously described (FACS Canto II, BD Bioscience) [10].
Statistics analysis
Variables were tested for a normal distribution using qq-plots and histograms. Variables show-
ing skewed distributions were logarithmically transformed for further analysis. Differences
across categorical variables were accessed using Pearson χ2 test, whereas continuous variables
were tested using the One Way Analysis of Variance on Ranks adjusted with a Bonferroni
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correction for multiple testing. Differences between episodes of complications or death in each
group were tested using the log-rank test. Univariate analysis was carried out to identify the
baseline factors associated with occurrence of complications or death. A logistic regression
model was then fitted including all the significant potential predictors from the univariate anal-
ysis. Categorical variables are presented as frequencies and percentages, continuous parameters
as mean ± SD. P-values<0.05 were considered statistically significant.
Results
Patient characteristics
One-hundred-and-six outpatients with clinically stable liver cirrhosis (age 58±10 years; 67 men
(63%); Child-Pugh class A: 5%, B: 67%, C: 28%; MELD score 15±6) with no previous history of
overt HE were prospectively included over a 2-year period. The aetiologies included viral
(n = 44), alcohol (n = 43), mixed viral plus alcohol (n = 13), primary biliary cirrhosis (n = 2),
non-alcohol steatohepatitis (n = 1), or unknown (n = 3). The severity of liver disease was
assessed by the Model for End-Stage Liver Disease (MELD) [20] and the Child-Pugh (C-P)
score [21]. Forty-four patients were diagnosed as having Grade 1 HE based on the West Haven
criteria. Of the 44 grade 1 HE patients, 14 (32%) showed lack of awareness, 18 (41%) experi-
enced euphoria or anxiety, 22 (50%) had shortened attention span and 19 (43%) showed
impaired performance of addition. 22 (50%) of the patients had one symptom, 17 (38%) had
two symptoms, 3 (7%) had three symptoms and 2 (5%) had all four symptoms. None of the
patients classified as ‘unimpaired’ or ‘mHE’ showed these signs or symptoms. Thirty-nine
patients were classified as having mHE based on at least one abnormal test (EEG, PHES, CFF).
Of the 39 mHE patients, 19 (49%) had one abnormal test, 13 (33%) had two abnormal tests
and 7 (18%) had abnormal outcomes in all three tests. Twenty-three patients were classified as
being unimpaired. The patients in the 3-cohorts were followed up for a mean of 234±99 (no
HE), 231±100 (mHE) and 227±89 (grade 1 HE) days.
The MELD score was similar in the three groups, whereas mHE patients had higher C-P
scores compared to Grade 1 HE patients (P = 0.005). Also, there was a significant difference in
extent of ascites; with 98% of Grade 1 HE patients having moderate-severe ascites (P = 0.003)
(Table 1). No differences between the three groups in bilirubin, INR, albumin, sodium, creati-
nine or WBC count levels were observed. Ammonia levels were similar in patients with mHE
and Grade 1 HE but significantly lower in the no HE group (P<0.001, respectively) (Table 1).
Ammonia levels were higher in patients with abnormal EEG compared to patients with abnor-
mal PHES test (P<0.001) (Table 2).
Complications and mortality
The three groups had significantly different rates of complications requiring hospital admission
(unimpaired/ mHE/ Grade 1 HE: 26/ 36/ 64% respectively; P = 0.02) (Fig 1A). Patients with
Grade 1 HE had more complications compared to patients with no HE and mHE (P = 0.01).
Infection was the most common complication requiring hospitalisation (unimpaired/ mHE/
Grade 1 HE: 9/ 18/ 34% respectively; P = 0.04), followed by HE (unimpaired/ mHE/ Grade 1
HE: 4/ 8/ 18% respectively; NS), and others (variceal bleeding, ascites) (unimpaired/ mHE/
Grade 1 HE: 13/ 10/ 11%; respectively; NS). MELD score, HE grade and bilirubin level, ammo-
nia and neutrophil respiratory burst were significantly higher in patients developing complica-
tions requiring hospitalisation than in those who did not, at univariate analysis (Table 3).
These variables were introduced into a logistic regression model disclosing HE grade 1
(OR = 3.8; 95%CI: 1.05–14.04; P = 0.04) and bilirubin (OR = 1.01; 95%CI: 1.00–1.02; P = 0.01)
as independent predictors of developing complications requiring hospitalisation.
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Mortality was significantly different between the three groups (unimpaired/ mHE/ Grade 1
HE: 4/ 5/ 20% respectively; P = 0.04) with Grade 1 HE patients having greater mortality than
mHE patients (P = 0.04) (Fig 1B). Univariate analysis demonstrated significantly higher base-
line levels of HE grade, ammonia and neutrophil respiratory burst in patients who died com-
pared to those who survived, whereas bacterial DNA positivity was not significantly associated
with mortality (Table 3). However, only neutrophil respiratory burst (OR = 1.03; 95%CI: 1.00–
1.07; P<0.05) was an independent predictor of mortality in a logistic regression model.
Bacterial DNA, neutrophil respiratory burst and phagocytosis
A difference in the prevalence of bacterial DNA positivity between the three groups was
observed (P = 0.01) (Table 1). Patients with Grade 1 HE had increased rates of detectable bacte-
rial DNA (57%) compared to patients with no HE (22%; P = 0.02) and mHE (36%; P = 0.06).
However, the presence or the absence of bacterial DNA did not predict which patients were
likely to develop complications or die (Table 3).
There was no difference in neutrophil phagocytosis between the three groups, whilst sponta-
neous neutrophil respiratory burst was higher in the patients with Grade 1 HE (22±22%)
Table 1. Baseline characteristics of patients with cirrhosis according to hepatic encephalopathy classification.
Unimpaired mHE Grade 1 HE P-value P-value
n = 23 n = 39 n = 44 (all 3 groups) (mHE/grade 1)
Sex: m/f (%) 74/26 62/38 59/41 P = 0.47
Age (year) 59 ± 6 58 ± 10 58 ± 12 P = 0.79
MELD 15 ± 6 14 ± 6 16 ± 6 P = 0.12
C-P score: A/B/C (%) 0/70/30 8/49/43 4/82/14 P = 0.019 P = 0.005
Ascites: 0/1/2 (%) 17/17/65 18/15/67 0/2/98 P = 0.003 P = 0.001
Abnormal EEG n (%) 0 21 (54) 24 (55) P<0.001 P = 0.95
Abnormal PHES n (%) 0 24 (62) 40 (93) P<0.001 P = 0.001
Abnormal CFF n (%) 0 21 (68) 36 (84) P<0.001 P = 0.19
Bilirubin (μmol/L) 76 ± 97 85 ± 88 65 ± 49 P = 0.50
INR 1.5 ± 0.3 1.5 ± 0.4 1.5 ± 0.3 P = 0.98
Albumin (g/dL) 2.8 ± 0.7 2.9 ± 0.5 2.9 ± 0.5 P = 0.67
Ammonia (μmol/L) 48 ± 11 61 ± 14 62 ± 12 P<0.001 P = 0.53
Sodium (mmol/L) 136 ± 5 136 ± 6 135 ± 5 P = 0.58
Creatinine (μmol/L) 91 ± 60 69 ± 39 81 ± 43 P = 0.18
WBC count (x 109/L) 5.0 ± 2.2 6.5 ± 3.1 7.4 ± 4.8 P = 0.05
Bacterial DNA n (%) 5 (22) 14 (36) 25 (57) P = 0.01 P = 0.06
Neut. resp. burst (%) 13 ± 11 13 ± 14 22 ± 22 P = 0.03 P = 0.02
Phagocytosis (GMFI) 84 ± 15 81 ± 13 78 ± 10 P = 0.16
Complications n (%) 6 (26) 14 (36) 28 (64) P = 0.02 P = 0.01
− Infections n (%) 2 (9) 7 (18) 15 (34) P = 0.04 P = 0.10
− HE n (%) 1 (4) 3 (8) 8 (18) P = 0.16
− Variceal bleed n (%) 1 (4) 2 (5) 2 (5) P = 0.99
− Ascites n (%) 1 (4) 2 (5) 3 (7) P = 0.90
− Unknown n (%) 1 (4) 0 (0) 0 (0) P = 0.16
Death n (%) 1 (4) 2 (5) 9 (20) P = 0.04 P = 0.04
HE = hepatic encephalopathy, MELD = Model for End-Stage Liver Disease, C-P score = Child-Pugh score, PHES = psychometric hepatic encephalopathy
score, CFF = critical ﬂicker frequency, WBC = white blood cell count, GMFI = geometric mean of ﬂuorescence intensity.
doi:10.1371/journal.pone.0146076.t001
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compared to patients with no HE (13±11%) and mHE (13±14%) (P = 0.03) (Table 1). Higher
respiratory burst was associated with an increased risk of cirrhosis complications requiring
hospital admission and with mortality (Table 3). ROC curve analysis showed that spontaneous
respiratory burst was indeed a good predictor of mortality (AUROC 0.79) (Fig 2). A cut off of
19.8% had sensitivity of 75% and specificity of 69%. Mortality was significantly higher in the
group of patients with values19.8% compared to the group with values<19.8% (22 vs. 6%;
P = 0.03) (Table 4 and Fig 3).
Discussion
The results of this study show that patients with Grade 1 HE have significantly more cirrhosis-
related complications and higher mortality compared to patients with mHE indicating that
‘Covert HE’ is indeed a heterogeneous entity comprising clinically and pathophysiologically
distinct syndromes. In fact, the occurrence of Grade 1 HE was a strong predictor of signifi-
cantly worsened prognosis, whilst the clinical outcomes of patients with mHE were similar to
the unimpaired group. HE is manifested by a continuum of symptoms and the categorisation
into grades is based on detectable symptoms and not on prognosis, recognising full well that
sometimes the diagnosis of Grade 1 HE may be difficult to make with certainty. However, the
prognostic differences between the groups with grade 1 HE and mHE described may provide
Table 2. Baseline characteristics of patients with cirrhosis according to test abnormalities.
Abnormal Abnormal 2–3 abnormal tests P-value
Unimpaired EEG only PHES only (incl. PHES)* (all groups)
n = 23 n = 10 n = 11 n = 53
Sex: m/f (%) 74/26 40/60 64/36 62/38 P = 0.33
Age (year) 59 ± 6 63 ± 8 51 ± 7 59 ± 12 P = 0.04
MELD 15 ± 6 15 ± 5 14 ± 4 16 ± 7 P = 0.80
Ascites: 0/1/2 (%) 17/17/65 10/20/70 9/27/64 7/4/89 P = 0.14
Grade 1 HE n (%) 0 (0) 1 (10) 4 (36) 36 (68) P<0.001
Bilirubin (μmol/L) 76 ± 97 55 ± 28 55 ± 30 80 ± 83 P = 0.67
INR 1.5 ± 0.3 1.5 ± 0.4 1.4 ± 0.2 1.5 ± 0.3 P = 0.91
Albumin (g/dL) 2.8 ± 0.7 3.0 ± 0.3 3.1 ± 0.5 2.9 ± 0.5 P = 0.62
Ammonia (μmol/L) 48 ± 11 71 ± 12 53 ± 6 61 ± 14 P<0.001
Sodium (mmol/L) 136 ± 5 136 ± 7 136 ± 5 135 ± 5 P = 0.84
Creatinine (μmol/L) 91 ± 60 82 ± 36 69 ± 19 78 ± 48 P = 0.58
WBC count (x 109/L) 5.0 ± 2.2 5.6 ± 3.1 4.8 ± 2.5 7.6 ± 4.4 P = 0.01
Bacterial DNA n (%) 5 (22) 4 (40) 7 (63) 23 (43) P = 0.11
Neut. resp. burst (%) 13 ± 11 19 ± 18 26 ± 22 17 ± 19 P = 0.21
Phagocytosis (GMFI) 84 ± 15 81 ± 10 80 ± 14 79 ± 11 P = 0.41
Complications n (%) 6 (26) 3 (30) 3 (27) 32 (60) P = 0.02
− Infections n (%) 2 (9) 1 (10) 0 (0) 16 (30) P = 0.09
− HE n (%) 1 (4) 0 (0) 2 (18) 9 (17) P = 0.25
− Others n (%) 3 (13) 2 (20) 1 (9) 7 (13) P = 0.81
Death n (%) 1 (4) 0 (0) 0 (0) 11 (21) P = 0.05
*current recommendation for diagnosis of mHE.
Left out ‘abnormal critical ﬂicker frequency (CFF) only’ because of only 3 patients in the group.
PHES = psychometric hepatic encephalopathy score, MELD = Model for End-Stage Liver Disease, HE = hepatic encephalopathy, WBC = white blood cell
count, GMFI = geometric mean of ﬂuorescence intensity.
doi:10.1371/journal.pone.0146076.t002
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Fig 1. Time from inclusion to development of first liver related complication requiring hospitalisation
(A) and survival curves for patients with no HE, mHE and Grade 1 HE (B). Dashed line depicts
unimpaired patients (n = 23), dotted line patients with mHE (n = 39) and solid line patients with Grade 1 HE
(n = 44) (P = 0.02 (A) and P = 0.04 (B)).
doi:10.1371/journal.pone.0146076.g001
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Table 3. Baseline characteristics of patients with cirrhosis developing complications requiring hospitalisation (Yes) and those who did not (No)
and of survivors versus non-survivors.
Complications Death
Yes (n = 48) No (n = 58) P-value Yes (n = 12) No (n = 94) P-value
Sex: m/f (%) 60/40 66/34 P = 0.59 75/25 62/38 P = 0.37
Age (year) 57 ± 11 59 ± 10 P = 0.24 57 ± 10 58 ± 10 P = 0.80
MELD 17 ± 6 14 ± 5 P = 0.005 16 ± 5 15 ± 6 P = 0.77
Ascites: 0/1/2 (%) 8/4/88 12/16/72 P = 0.11 8/0/92 11/12/77 P = 0.42
No/mHE/grade 1 HE (%) 13/29/58 29/43/28 P = 0.005 8/17/75 24/39/37 P = 0.04
Bilirubin (μmol/L) 95 ± 97 58 ± 50 P = 0.01 91 ± 91 73 ± 75 P = 0.42
INR 1.6 ± 0.3 1.4 ±0.3 P = 0.05 1.6 ± 0.4 1.5 ± 0.3 P = 0.09
Albumin (g/dL) 2.9 ± 0.5 2.9 ± 0.6 0 = 0.59 2.8 ± 0.6 2.9 ± 0.5 P = 0.49
Ammonia (μmol/L) 62 ± 14 56 ± 13 P = 0.03 67 ± 18 57 ± 13 P = 0.03
Sodium (mmol/L) 135 ± 5 135 ± 5 P = 0.95 134 ± 5 135 ± 5 P = 0.24
Creatinine (μmol/L) 80 ± 44 78 ± 47 P = 0.83 58 ± 21 81 ± 48 P = 0.10
WBC count (x 109/L) 6.9 ± 3.6 6.2 ± 4.0 P = 0.31 7.0 ± 2.0 6.5 ± 4.0 P = 0.67
Bacterial DNA n (%) 22 (46) 22 (38) P = 0.41 5 (42) 39 (41) P = 0.99
Neut. resp. burst (%) 22 ± 19 13 ± 15 P = 0.005 33 ± 22 15 ± 16 P<0.001
Phagocytosis (GMFI) 78 ± 12 82 ± 13 P = 0.13 75 ± 11 81 ± 13 P = 0.14
MELD = Model for End-Stage Liver Disease, HE = hepatic encephalopathy, WBC = white blood cell count, GMFI = geometric mean of ﬂuorescence
intensity.
doi:10.1371/journal.pone.0146076.t003
Fig 2. Receiver operating characteristic (ROC) of analyses of neutrophil respiratory burst. Receiver
operating characteristic (ROC) of analyses of neutrophil respiratory burst as a predictor for mortality in
cirrhotic patients. Selected cut-off for neutrophil respiratory burst 19.8%marked with X.
doi:10.1371/journal.pone.0146076.g002
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Table 4. Baseline characteristics of patients with cirrhosis according to neutrophil respiratory burst.
Neutrophil < 19.8%  19.8% P-value
respiratory burst (n = 69) (n = 37)
Sex: m/f (%) 65/35 59/41 P = 0.56
Age (year) 59 ± 10 57 ± 10 P = 0.28
MELD 15 ± 6 16 ± 6 P = 0.37
Ascites: 0/1/2 (%) 13/10/77 5/11/84 P = 0.47
No/mHE/grade 1 HE (%) 23/42/35 19/27/54 P = 0.15
Bilirubin (μmol/L) 73 ± 71 78 ± 87 P = 0.73
INR 1.5 ± 0.4 1.5 ± 0.3 P = 0.79
Albumin (g/dL) 2.9 ± 0.6 2.9 ± 0.5 P = 0.44
Ammonia (μmol/L) 58 ± 13 60 ± 16 P = 0.42
Sodium (mmol/L) 135 ± 5 135 ± 5 P = 0.77
Creatinine (μmol/L) 78 ± 49 80 ± 40 P = 0.81
WBC count (x 109/L) 6.2 ± 3.7 7.2 ± 4.0 P = 0.19
Bacterial DNA n (%) 28 (41) 16 (43) P = 0.79
Phagocytosis (GMFI) 82 ± 13 78 ± 12 P = 0.14
Complications n (%) 24 (35) 24 (65) P = 0.03
Mortality n (%) 4 (6) 8 (22) P = 0.03
MELD = Model for End-Stage Liver Disease, HE = hepatic encephalopathy, WBC = white blood cell count, GMFI = geometric mean of ﬂuorescence
intensity.
doi:10.1371/journal.pone.0146076.t004
Fig 3. Survival curves for patients according to neutrophil respiratory burst. Survival curves for patients
with neutrophil respiratory burst <19.8% (n = 69, solid line) and19.8% (n = 37, dashed line) (P = 0.03).
doi:10.1371/journal.pone.0146076.g003
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the argument to try and separate the ‘Covert’ group into its subcomponents, even if such a dis-
tinction is difficult.
The diagnosis of mHE is based on both neurophysiological and psychometric tests. We clas-
sified patients as having mHE based on at least one abnormal test using three different cur-
rently validated testing strategies. It is not clear which cirrhotic patients will display
abnormalities in the different tests and the EASL/AASLD guidelines suggest that when testing
for mHE at least two validated testing strategies should be utilized, one of them being PHES [8,
22]. Pathophysiologically, it is also known that many brain regions are differently affected in
individual patients supporting the notion that mHE may manifest with multidimensional neu-
ropsychiatric symptoms ranging from abnormalities in cognition, attention, memory, anxiety
and depression. Thus, it was not surprising that about half of the mHE patients had only one
abnormal test to allow diagnosis of mHE. Only about 20% patients had abnormal outcomes in
all three tests. In an additional analysis, we re-classified our patients to diagnose mHE as
defined by abnormality of two tests (as suggested by the EASL/AASLD guidelines), one of
them being PHES. The overall results were similar in terms of complications and mortality
between the three groups (Table 5).
Of the patients with at least 2 abnormal tests, almost 70% had grade 1 HE. Also WBC levels
were higher in these patients demonstrating the important synergetic effect of inflammation in
the development of HE. Complication rate and mortality were similar when comparing
patients with abnormal EEG and PHES only, while having at least two abnormal tests,
increased the risk significantly. Similar findings were recently reported by Montagnese et al
and Lauridsen et al [23, 24]. Any division of HE into grades is clearly a simplification based on
symptoms and not on prognosis. A possible solution to better discriminate patients who do
not have ‘overt’ HEmay be to classify them according to number of abnormal tests. In this
model, a patient with ‘Covert HE’ may be classified into a low-risk group, identified by the
presence of one abnormal test, whereas the presence of 2 abnormal tests would identify a high-
risk group instead of the challenging diagnosis of Grade 1 HE. Hereby, it might be possible to
distinguish between groups with different prognosis. This hypothesis will need to be tested in
future studies.
Although the literature suggests that the occurrence of overt HE is more common in mHE
compared to unimpaired patients [5, 6], the present study did not show a significant difference.
This discrepancy may be explained by either too few events in our study due to short period of
observation or by patients with previous history of ‘overt HE’ being included in the other stud-
ies. In fact, 28% of patients with mHE had previous episodes of ‘overt HE’ compared with 4%
of the unimpaired patients in the study by Hartmann et al [6]. Alternatively, it is possible that
at least some of the patients diagnosed with mHE in those previous studies may have had undi-
agnosed Grade 1 HE despite the fact that ‘presence of HE’ was an exclusion criteria. As sug-
gested by the EASL/AASLD HE guidelines, that unless specific examination is performed to
look for evidence of Grade 1 HE, its diagnosis can be missed [7].
The data also showed that infection was the most common complication in patients with
Grade 1 HE. Conversely, MELD scores and synthetic liver function tests including ammonia,
albumin, INR and bilirubin levels were similar in the three groups. The underlying mechanism
linking the presence of Grade 1 HE and increased complications and mortality, despite other-
wise similar severity of liver disease, is uncertain. Although white blood cell counts were not
different between patients with mHE and Grade 1 HE, patients with Grade 1 HE had more fre-
quent evidence of bacterial translocation and higher spontaneous neutrophil respiratory burst
compared to patients with mHE. Neutrophil dysfunction was also an independent risk factor
of mortality. These findings indicate a potential mechanistic link between neutrophil dysfunc-
tion and increased risk of infection. Studies in animal models and in patients with stroke
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suggest that immune dysfunction may well be a consequence of brain dysfunction [25–28]. In
animal models, mild occlusion of the middle cerebral artery was shown to result in immune
dysfunction resulting in reduced ability to clear infection that was introduced iatrogenically
into the lungs [25]. In keeping with this observation, there is increased risk of bacterial infec-
tion in patients with stroke, which is also one of the main causes of death of patients with
stroke. Therefore, it is possible that HE may independently result in neutrophil dysfunction
making patients more susceptible to infection rather than being its consequence. This hypothe-
sis will need to be confirmed in future studies.
Increased spontaneous neutrophil burst was predictive of subsequent infection and organ
dysfunction in patients with alcoholic hepatitis [10]. Bacterial DNA has been demonstrated to
result in neutrophil activation [29] and studies suggest that endotoxemia is one of the possible
causes of spontaneous neutrophil burst and hypothesize that the underlying mechanism may
be increased gut permeability, which is a well-known feature of cirrhosis [10, 30, 31]. Increased
bacterial translocation is common in patients with ascites and its frequency correlates with the
severity of liver failure [32, 33]. The Grade 1 HE patients had higher prevalence of ascites and
also a non-significantly higher rate of bacterial DNA in their plasma [19]. The mechanism of
the higher frequency of ascites and bacterial DNA in Grade 1 HE is not clear but it is interest-
ing to consider the potential role of the autonomic nervous system in modulating the severity
of gut inflammation [34]. Newton et al. suggested that in patients with primary biliary cirrhosis
with cognitive impairment, autonomic dysfunction is prevalent [35]. Therefore, the observa-
tion of Wiest et al. that splanchnic sympathectomy in an animal model reduced bacterial trans-
location of gram negative organisms suggests a possible link between bacterial translocation
and HE [36]. This hypothesis will need to be tested in suitable models.
Table 5. Baseline characteristics of patients with cirrhosis according to the hepatic encephalopathy classification (2 tests abnormal for diagnosis
of mHE).
No HE mHE* Grade 1 HE P-value
n = 45 n = 17 n = 44 (all 3 groups)
Sex: m/f (%) 62/38 62/38 59/41 P = 0.44
Age (year) 59 ± 7 58 ± 12 58 ± 12 P = 0.83
MELD 14 ± 5 14 ± 7 16 ± 6 P = 0.17
Ascites: 0/1/2 (%) 16/20/64 23/6/71 0/2/98 P = 0.001
Bilirubin (μmol/L) 70 ± 74 111 ± 122 65 ± 49 P = 0.09
INR 1.5 ± 0.3 1.5 ± 0.4 1.5 ± 0.3 P = 0.90
Albumin (g/dL) 2.8 ± 0.6 2.9 ± 0.7 2.9 ± 0.5 P = 0.63
Ammonia (μmol/L) 56 ± 14 56 ± 15 62 ± 12 P = 0.06
Sodium (mmol/L) 136 ± 6 136 ± 4 135 ± 5 P = 0.59
Creatinine (μmol/L) 81 ± 47 68 ± 51 81 ± 43 P = 0.60
WBC count (x 109/L) 5.5 ± 2.9 7.0 ± 2.5 7.4 ± 4.8 P = 0.06
Bacterial DNA n (%) 14 (31) 5 (29) 25 (57) P = 0.03
Neut. resp. burst (%) 15 ± 14 9 ± 9 22 ± 22 P = 0.01
Phagocytosis (GMFI) 83 ± 14 82 ± 14 78 ± 10 P = 0.25
Complications n (%) 12 (27) 8 (47) 28 (64) P = 0.02
Death n (%) 1 (2) 2 (12) 9 (20) P = 0.03
*at least 2 abnormal tests (one being PHES) for diagnosis of mHE.
HE = hepatic encephalopathy, MELD = Model for End-Stage Liver Disease, WBC = white blood cell count, GMFI = geometric mean of ﬂuorescence
intensity.
doi:10.1371/journal.pone.0146076.t005
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We observed no difference in ammonia levels between patients with mHE and Grade 1 HE.
Ammonia levels were not an independent predictor of outcome, although values were higher
in the patients who developed complications requiring hospital admission and those who died.
Ammonia has been shown to be important in the pathogenesis of neutrophil dysfunction [11]
but we did not observe any direct correlation between the severity of neutrophil dysfunction
and ammonia levels indicating other operative mechanisms underlying its pathogenesis. In a
recent study, Montagnese et al showed that EEG abnormalities in patients with cirrhosis were
associated with higher ammonia levels compared to patients with impaired PHES perfor-
mance, pointing to possibly different mechanisms underlying the mHE phenotypes [37]. This
finding was confirmed in our study as patients with abnormal EEG also had higher ammonia
levels compared to patients with abnormal PHES test. These data provide further evidence that
from the pathophysiological perspective, mHE is also a heterogenous entity and therefore the
treatment approaches for patients presenting with different abnormalities in psychometric
tests may well be different.
In conclusion, the results of this study show for the first time that ‘Covert HE’ is a heteroge-
neous entity comprising two clinically and pathophysiologically distinct syndromes that should
be described separately until more data are available. Infection is the most common complica-
tion necessitating hospital admission in Grade 1 HE patients and this is associated with higher
rates of bacterial translocation and neutrophil dysfunction. Further studies should address
whether this is a cause or consequence of HE.
Author Contributions
Conceived and designed the experiments: RJ. Performed the experiments: JM GT. Analyzed
the data: KLT RJ. Contributed reagents/materials/analysis tools: JM GT. Wrote the paper: KLT
RJ RM.
References
1. Cordoba J, Ventura-Cots M, Simon-Talero M, Amoros A, Pavesi M, Vilstrup H, et al. Characteristics,
risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without
acute-on-chronic liver failure (ACLF). J Hepatol. 2014; 60(2):275–81. doi: 10.1016/j.jhep.2013.10.004
PMID: 24128414.
2. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V, et al. Prognostic significance of
hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999; 30(5):890–5. PMID: 10365817.
3. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a
Danish population-based cohort study. Hepatology. 2010; 51(5):1675–82. doi: 10.1002/hep.23500
PMID: 20186844.
4. Stewart CA, Malinchoc M, KimWR, Kamath PS. Hepatic encephalopathy as a predictor of survival in
patients with end-stage liver disease. Liver Transpl. 2007; 13(10):1366–71. doi: 10.1002/lt.21129
PMID: 17520742.
5. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic
encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;
96(9):2718–23. doi: 10.1111/j.1572-0241.2001.04130.x PMID: 11569701.
6. Hartmann IJ, GroenewegM, Quero JC, Beijeman SJ, de Man RA, HopWC, et al. The prognostic signifi-
cance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000; 95(8):2029–34. doi: 10.1111/j.
1572-0241.2000.02265.x PMID: 10950053.
7. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and rec-
ommendations. J Hepatol. 2005; 42 Suppl(1):S45–53. doi: 10.1016/j.jhep.2004.11.028 PMID:
15777572.
8. American Association for the Study of Liver D, European Association for the Study of the L. Hepatic
encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the
Study of the Liver and the American Association for the Study of Liver Diseases. J Hepatol. 2014; 61
(3):642–59. doi: 10.1016/j.jhep.2014.05.042 PMID: 25015420.
Covert HE: One Condition or Two?
PLOSONE | DOI:10.1371/journal.pone.0146076 January 8, 2016 12 / 14
9. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al. Review article: the
design of clinical trials in hepatic encephalopathy—an International Society for Hepatic Encephalopa-
thy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011; 33
(7):739–47. doi: 10.1111/j.1365-2036.2011.04590.x PMID: 21306407; PubMed Central PMCID:
PMC3971432.
10. Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA, et al. Neutrophil dysfunction
in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology.
2007; 46(3):831–40. doi: 10.1002/hep.21737 PMID: 17680644.
11. Shawcross DL, Wright GA, Stadlbauer V, Hodges SJ, Davies NA, Wheeler-Jones C, et al. Ammonia
impairs neutrophil phagocytic function in liver disease. Hepatology. 2008; 48(4):1202–12. doi: 10.1002/
hep.22474 PMID: 18697192.
12. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammo-
nia levels and the severity of hepatic encephalopathy. Am J Med. 2003; 114(3):188–93. PMID:
12637132.
13. Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic
encephalopathy. Metab Brain Dis. 2013; 28(1):1–5. doi: 10.1007/s11011-012-9370-2 PMID:
23224356.
14. Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al. Infection and systemic
inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in
cirrhosis. J Hepatol. 2011; 54(4):640–9. doi: 10.1016/j.jhep.2010.07.045 PMID: 21163546.
15. Tritto G, Bechlis Z, Stadlbauer V, Davies N, Frances R, Shah N, et al. Evidence of neutrophil functional
defect despite inflammation in stable cirrhosis. J Hepatol. 2011; 55(3):574–81. doi: 10.1016/j.jhep.
2010.11.034 PMID: 21236309.
16. Van der Rijt CC, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encepha-
lopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol. 1984; 57
(5):423–6. PMID: 6201336.
17. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization
of hepatic encephalopathy. J Hepatol. 2001; 34(5):768–73. PMID: 11434627.
18. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quan-
tification of low-grade hepatic encephalopathy. Hepatology. 2002; 35(2):357–66. doi: 10.1053/jhep.
2002.30957 PMID: 11826409.
19. Such J, Frances R, Munoz C, Zapater P, Casellas JA, Cifuentes A, et al. Detection and identification of
bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology. 2002;
36(1):135–41. doi: 10.1053/jhep.2002.33715 PMID: 12085357.
20. Kamath PS, Wiesner RH, MalinchocM, KremersW, Therneau TM, Kosberg CL, et al. A model to predict
survival in patients with end-stage liver disease. Hepatology. 2001; 33(2):464–70. PMID: 11172350
21. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 1973; 60(8):646–9. PMID: 4541913.
22. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in
chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Dis-
eases and the European Association for the Study of the Liver. Hepatology. 2014; 60(2):715–35. doi:
10.1002/hep.27210 PMID: 25042402.
23. Montagnese S, Balistreri E, Schiff S, De Rui M, Angeli P, Zanus G, et al. Covert hepatic encephalopa-
thy: agreement and predictive validity of different indices. World J Gastroenterol. 2014; 20(42):15756–
62. doi: 10.3748/wjg.v20.i42.15756 PMID: 25400460; PubMed Central PMCID: PMC4229541.
24. Lauridsen MM, Schaffalitzky de Muckadell OB, Vilstrup H. Minimal hepatic encephalopathy character-
ized by parallel use of the continuous reaction time and portosystemic encephalopathy tests. Metab
Brain Dis. 2015. doi: 10.1007/s11011-015-9688-7 PMID: 26016624.
25. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune
deficiency syndrome. Nat Rev Neurosci. 2005; 6(10):775–86. doi: 10.1038/nrn1765 PMID: 16163382.
26. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel C, Ziemssen T, et al. Stroke-induced immunodepres-
sion: experimental evidence and clinical relevance. Stroke. 2007; 38(2 Suppl):770–3. doi: 10.1161/01.
STR.0000251441.89665.bc PMID: 17261736.
27. Emsley HC, Hopkins SJ. Post-stroke immunodepression and infection: an emerging concept. Infect
Disord Drug Targets. 2010; 10(2):91–7. PMID: 20166972.
28. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency pro-
motes spontaneous bacterial infections and is mediated by sympathetic activation reversal by post-
stroke T helper cell type 1-like immunostimulation. J Exp Med. 2003; 198(5):725–36. doi: 10.1084/jem.
20021098 PMID: 12939340; PubMed Central PMCID: PMC2194193.
Covert HE: One Condition or Two?
PLOSONE | DOI:10.1371/journal.pone.0146076 January 8, 2016 13 / 14
29. El Kebir D, Jozsef L, Filep JG. Neutrophil recognition of bacterial DNA and Toll-like receptor 9-depen-
dent and -independent regulation of neutrophil function. Arch Immunol Ther Exp (Warsz). 2008; 56
(1):41–53. doi: 10.1007/s00005-008-0008-3 PMID: 18250968.
30. Etheredge EE, Spitzer JA. Chronic endotoxemia reversibly alters respiratory burst activity of circulating
neutrophils. J Surg Res. 1993; 55(3):261–8. doi: 10.1006/jsre.1993.1138 PMID: 8412108.
31. Bohmer RH, Trinkle LS, Staneck JL. Dose effects of LPS on neutrophils in a whole blood flow cyto-
metric assay of phagocytosis and oxidative burst. Cytometry. 1992; 13(5):525–31. doi: 10.1002/cyto.
990130512 PMID: 1321708.
32. Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccha-
ride binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatol-
ogy. 2003; 37(1):208–17. doi: 10.1053/jhep.2003.50038 PMID: 12500206.
33. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taura P, et al. Bacterial translocation of enteric organ-
isms in patients with cirrhosis. J Hepatol. 2001; 34(1):32–7. PMID: 11211904.
34. Straub RH, Wiest R, Strauch UG, Harle P, Scholmerich J. The role of the sympathetic nervous system
in intestinal inflammation. Gut. 2006; 55(11):1640–9. doi: 10.1136/gut.2006.091322 PMID: 17047110;
PubMed Central PMCID: PMC1860105.
35. Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, et al. Cognitive
impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology. 2008; 48
(2):541–9. doi: 10.1002/hep.22371 PMID: 18563843.
36. Worlicek M, Knebel K, Linde HJ, Moleda L, Scholmerich J, Straub RH, et al. Splanchnic sympathec-
tomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut. 2010; 59
(8):1127–34. doi: 10.1136/gut.2009.185413 PMID: 20519743.
37. Montagnese S, Biancardi A, Schiff S, Carraro P, Carla V, Mannaioni G, et al. Different biochemical cor-
relates for different neuropsychiatric abnormalities in patients with cirrhosis. Hepatology. 2011; 53
(2):558–66. doi: 10.1002/hep.24043 PMID: 21274876.
Covert HE: One Condition or Two?
PLOSONE | DOI:10.1371/journal.pone.0146076 January 8, 2016 14 / 14
